ASTHMA CLINICAL RESEARCH NETWORK CENTER

这份申请书提议继续让调查人员参与 在UCSF的六个中心的互动网络中，哮喘临床 研究网络（ACRN）在进行新疗法的研究， 哮喘和传播研究结果的实践社区。 的 死亡率的增加表明需要这样一个网络， 哮喘的发病率、患病率和费用，研究表明， 哮喘与气道炎症有关， 潜在有效的发展速度，但也可能 昂贵的治疗。 定义这些新疗法的位置， 因为这需要多中心的合作研究 反映了美国人口的多样性。 在最初的5年里， ACRN建立了一个交互式基础设施，并增加了一个研究 位于纽约的哈莱姆医院，主要为少数族裔服务 人口 ACRN完成并发表了关于 在轻度哮喘（“BAGS”）中定期使用β-激动剂及其疗效 秋水仙碱作为吸入性皮质类固醇（ICS）的替代品， 中度哮喘 目前，该公司正在进行一项试验， β-激动剂，ICS，以及两者的组合， 严重哮喘 我们即将开始第五项研究， 不同的ICS对皮质醇分泌的影响相同。 这些 研究已经在ATS、ACCP和AAAAI的会议上提出， 有10-12项辅助研究分析临床性能 research. ACRN还报告了来自亚组的调查结果， “BAGS”研究的分析：不同基因型的受试者 β-肾上腺素能受体受到定期使用 沙丁胺醇这项申请建议继续参与加州大学旧金山分校 哮喘临床研究小组在多中心，协作 ACRN的审判。 拟议的研究包括比较 不同剂量吸入糖皮质激素的临床疗效 相同的全身效应，一项关于定期使用吸入 按β-肾上腺素能受体基因型分层的受试者中的β-受体激动剂 受体，一项关于白三烯通路拮抗剂功效的研究 能够减少或消除吸入性皮质类固醇治疗 在轻度或中度持续性哮喘受试者中，以及其他研究 在本申请中简要地示出，但是被修改或替换， ACRN指导委员会对新信息或新闻稿的回应 新形式的治疗。

This application proposes to continue the participation of investigators at UCSF in an interactive network of six centers, the Asthma Clinical Research Network (ACRN) in conducting studies of novel therapies for asthma and in disseminating findings to the practicing community. The need for such a network was suggested by increases in the mortality, morbidity, prevalence, and costs of asthma, by research studies showing that asthma is linked to airway inflammation, and by the accelerating rate of development of potentially effective, but also potentially costly treatments. Defining the place of these new therapies was seen as requiring collaborative, multi-center studies examining subjects reflecting the diversity of the U.S. population. In its first 5 years, the ACRN established an interactive infrastructure and added a research site at Harlem Hospital, New York, which serves a predominantly minority population. The ACRN completed and published trials of the effects of regular use of a Beta-agonist in mild asthma("BAGS") and of the efficacy of colchicine as an alternate to an inhaled corticosteroid (ICS) in moderate asthma. It is now conducting trials comparing a long-acting Beta-agonist, an ICS, and the combination of the two in moderate to severe asthma. We are about to start a 5th study to establish doses of different ICS with equivalent effects on cortisol secretion. These studies have been presented at meetings of the ATS, ACCP, and AAAAI, as have 10-12 ancillary studies analyzing the performance of clinical research. The ACRN has also reported its findings from subgroup analysis of the "BAGS" study: that subjects with different genotypes for the Beta-adrenergic receptor are differently affected by regular use of albuterol. This application proposes continued participation of the UCSF Asthma Clinical Research group in the multicentered, collaborative trials of the ACRN. The studies proposed include a comparison of the clinical efficacy of doses of different inhaled corticosteroids with equal systemic effects, a prospective study of regular use of an inhaled Beta-agonist in subjects stratified by genotypes for the Beta-adrenergic receptor, a study of the efficacy of a leukotriene pathway antagonist in enabling reduction or elimination of inhaled corticosteroid therapy in subjects with mild or moderate persistent asthma, and other studies illustrated briefly in this application, but modified or replaced by the ACRN Steering Committee in response to new information or the release of new forms of therapy.